Skip to main content

Table 2 Medications of the study patients before and after propensity score matching

From: Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke

Characteristics

Before matching

After matching

Linagliptin (n = 401)

Control (n = 17,227)

P

Control (n = 802)

P

Non-DM medication

 Aspirin

341 (85.0)

14,549 (84.5)

.750

682 (85.0)

1.000

 Clopidogrel

206 (51.4)

6696 (38.9)

< .001

393 (49.0)

.439

 Warfarin

24 (6.0)

1096 (6.4)

.760

47 (5.9)

.931

 NOAC

4 (1.0)

197 (1.1)

.785

8 (1.0)

1.000

 ACEI/ARB

275 (68.6)

10,829 (62.9)

.019

548 (68.3)

.930

 β-blocker

208 (51.9)

7388 (42.9)

< .001

421 (52.5)

.838

 CCB

209 (52.1)

8963 (52.0)

.971

431 (53.7)

.595

 Digoxin

20 (5.0)

957 (5.6)

.623

45 (5.6)

.652

 Statin

218 (54.4)

8048 (46.7)

.002

443 (55.2)

.774

 NSAID

99 (24.7)

4321 (25.1)

.857

208 (25.9)

.640

 Cox-2 inhibitor

28 (7.0)

1493 (8.7)

.235

54 (6.7)

.871

 Diuretic

116 (28.9)

3528 (20.5)

< .001

217 (27.1)

.494

 Spironolactone

35 (8.7)

1355 (7.9)

.526

65 (8.1)

.712

 Fibrate

32 (8.0)

1242 (7.2)

.556

72 (9.0)

.562

DM medication

 Biguanide

156 (38.9)

8177 (47.5)

.001

331 (41.3)

.430

 Sulfonylurea

204 (50.9)

6864 (39.8)

< .001

445 (55.5)

.130

 Thiazolidinedione

27 (6.7)

869 (5.0)

.128

47 (5.9)

.553

 Alpha-glucosidase inhibitor

81 (20.2)

2037 (11.8)

< .001

165 (20.6)

.879

 Non-SU insulin secretagogue (Glinide)

93 (23.2)

2397 (13.9)

< .001

164 (20.4)

.274

 Insulin

244 (60.8)

7807 (45.3)

< .001

484 (60.3)

.868

  1. Values are the mean ± SD or n (%)
  2. ACEI/ARB angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker, CCB calcium channel blocker, DM diabetes mellitus, NOAC novel oral anticoagulant, Non-SU non-sulfonylurea, NSAID non-steroidal anti-inflammatory drug